2‐Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy

Abstract

Background. Given the chronic relapsing, remitting course of psoriasis, data about long-term effectiveness may be useful to assess the maintenance of clinical response over time. Objective. To evaluate 2-year drug survival of risankizumab and identify any predictive factor of discontinuation for ineffectiveness. Materials and Methods. A multicenter retrospective study was conducted in patients who initiated risankizumab between July 2019 and December 2020. PASI was measured at baseline and after 104 weeks. Any adverse event was registered during visits. Univariable and multivariable logistic regressions were used to assess baseline patients’ characteristics that predicted clinical response. The drug survival analysis was descriptively performed using the Kaplan–Meier survival curve. Results. 112 patients with moderate-to-severe plaque psoriasis were included. The overall median observation time was 35.3 months (26.7–37.3); the estimated survivor cumulative function at months 12 and 24 was 93.6% and 90.6%, respectively. No differences in BMI, disease duration, disease severity, or previous biological therapies were observed in patients who responded or did not respond to treatment. No significant adverse events were reported, but there was relapse of psoriatic arthritis and ulcerative colitis in a patient. Conclusions. We found that risankizumab was associated with long-term effectiveness, and a favorable safety profile in a population of psoriatic patients was observed, over a period of 2 years.

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

“…Summary drug survival curves in blue, separate studies in grey. A Secukinumab [ 24 – 26 , 33 , 34 , 39 – 41 , 44 , 46 , 48 , 50 , 51 , 53 , 62 , 64 , 68 , 70 , 72 , 74 , 80 – 85 ], B ixekizumab [ 23 , 32 , 33 , 39 , 40 , 42 – 44 , 46 , 49 , 62 , 70 , 81 , 84 , 85 ], C brodalumab [ 39 , 40 , 58 , 62 , 84 – 87 ], D guselkumab [ 29 , 30 , 33 , 35 , 37 , 43 , 44 , 50 , 59 , 70 , 84 , 85 , 88 , 89 ], E risankizumab [ 27 , 50 , 84 , 85 , 90 ], ...…”